A Unified Approach to Couple Aromatic Heteronucleophiles to Azines and Pharmaceuticals
作者:Ryan G. Anderson、Brianna M. Jett、Andrew McNally
DOI:10.1002/anie.201807322
日期:2018.9.17
Coupling aromatic heteronucleophiles to arenes is a common way to assemble drug‐like molecules. Many methods operate via nucleophiles intercepting organometallic intermediates, via Pd‐, Cu‐, and Ni‐catalysis, that facilitate carbon‐heteroatom bond formation and a variety of protocols. We present an alternative, unified strategy where phosphonium salts can replicate the behavior of organometallic intermediates
将芳香族异核试剂与芳烃偶联是组装类药物分子的常见方法。许多方法通过亲核试剂拦截有机金属中间体,通过 Pd、Cu 和 Ni 催化来进行,从而促进碳杂原子键的形成和各种方案。我们提出了一种替代的、统一的策略,其中鏻盐可以复制有机金属中间体的行为。在一组狭窄的反应条件下,多种芳香族杂核亲核试剂可以与吡啶和二嗪偶联,这在金属催化偶联中经常出现问题,例如在具有多个极性官能团的复杂结构中无法获得(假)卤化物前体。
[EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
申请人:BIOGEN IDEC INC
公开号:WO2014028669A1
公开(公告)日:2014-02-20
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.
Monoacylglycerollipase (MAGL) is an enzyme belonging to the endocannabinoid system that mainly metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG). Numerous studies have shown the involvement of this enzyme in various pathological conditions such as pain, cancer progression, Parkinson's and Alzheimer's disease, thus encouraging the development of new MAGL modulators. In this context, we
The present invention provides a compound of formula I
The compounds of formula I demonstrate properties as Smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.
1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
申请人:Sekiguchi Yoshinori
公开号:US20080318923A1
公开(公告)日:2008-12-25
It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.